Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Summary
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ('Monopar” or the 'Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...
Description
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ('Monopar” or the 'Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source